Usually, it is a twostep project:
a. In a first step selections are carried out and the resulting NGS-data is checked for matching QC-criteria. If the antibody is of limited quality and the QC is not passed, the customer will only pay the upfront fee covering this step.
b. In a second step, often in close exchange with the customer, the data is analyzed and further processed to identify the epitopes and, where necessary, peptides for all kinds of applications. See here.